Search Results

You are looking at 1 - 10 of 16 items for :

Clear All
Open access

Ana P Estrada-Flórez, Mabel E Bohórquez, Alejandro Vélez, Carlos S Duque, Jorge H Donado, Gilbert Mateus, Cesar Panqueba-Tarazona, Guadalupe Polanco-Echeverry, Ruta Sahasrabudhe, Magdalena Echeverry and Luis G Carvajal-Carmona

stage ( 1 , 10 , 11 ), although the evidence is not consistent ( 12 , 13 , 14 ). Hence, BRAF V600E on its own has limited utility as a prognosis PTC biomarker. More recently, two TERT promoter mutations, C228T and C250T, were found in ~10% of PTC

Open access

Huy Gia Vuong, Nguyen Phuoc Long, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Le Phi Hung, Tadao Nakazawa, Ryohei Katoh and Tetsuo Kondo

significantly higher as compared to classical PTC. The more recently discovered TERT promoter mutations were also more prevalent in TCVPTCs than in classical PTCs ( 9 , 29 ). The association of BRAF and TERT promoter mutations with a poor outcome in PTC

Open access

Huy Gia Vuong, Uyen N P Duong, Ahmed M A Altibi, Hanh T T Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi and Lewis Hassell

described genetic marker, TERT promoter mutations, has shown promise in predicting patient’s outcomes ( 8 , 9 ). The prognostic implications of RAS mutations and RET/PTC rearrangements in PTC are still controversial. In the present study, we

Open access

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana and Alessia Ciarrocchi

aggressive lesions from the vast majority of indolent PTCs ( 14 ). Furthermore, a recent report identifies mutations in MED12 and in TERT promoter as shared genetic features between ATC and fatal non-ATC thyroid lesions, hypothesizing a common genetic

Open access

Anello Marcello Poma, Riccardo Giannini, Paolo Piaggi, Clara Ugolini, Gabriele Materazzi, Paolo Miccoli, Paolo Vitti and Fulvio Basolo

lobectomy may be a sufficient treatment for low-risk FTC (i.e. MI-FTC with less than 4 vascular invasion foci) ( 12 ). However, molecular markers such as TERT promoter mutations were found to be an independent poor prognosis factor in differentiated

Open access

Catarina Tavares, Maria João Coelho, Catarina Eloy, Miguel Melo, Adriana Gaspar da Rocha, Ana Pestana, Rui Batista, Luciana Bueno Ferreira, Elisabete Rios, Samia Selmi-Ruby, Bruno Cavadas, Luísa Pereira, Manuel Sobrinho Simões and Paula Soares

of 96 cPTCs, demonstrating that the ones harboring BRAF V600E mutation expressed more often NIS in the cell membrane of tumor cells compared to BRAF WT cPTCs ( 28 ). Less is known about the impact of mutations in other genes (i.e. RAS and TERT p

Open access

Barbora Pekova, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Petr Vlcek, Pavla Sykorova, Daniela Kodetova, Josef Vcelak and Bela Bendlova

only in clinical-pathological features, but also in genetic alterations. Main PTC-activating somatic mutations in the RAS , BRAF and TERT genes and RET/PTC rearrangements cause uncontrolled activation of MAPK and PI3K signaling pathways. It was

Open access

Klaudia Zajkowska, Janusz Kopczyński, Stanisław Góźdź and Aldona Kowalska

NIFTP include PPARG fusions ( 4 , 27 , 33 ), THADA fusions ( 4 , 27 ) and BRAF K600E mutations ( 4 , 28 , 31 , 32 ). Rarely, tumours harbouring high-risk mutations such as TERT promoter mutations and ETV6-NTRK3 fusions may have a

Open access

Guoquan Zhu, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen and Jiaxin Luo

metastasis. In recent years, an increasing number of molecular genetic characteristics associated with invasiveness and clinical management have been uncovered, including the BRAF V600E mutation, TERT promoter mutations, RAS mutations and RET

Open access

Tiemo S Gerber, Arno Schad, Nils Hartmann, Erik Springer, Ulrich Zechner and Thomas J Musholt

have been no RAS and BRAF p.V600E variants in the same tissue sample. Mutations in BRAF , EIF1AX , TP53 and TERT are associated with aggressive behaviour of thyroid malignancies ( 2 , 8 , 12 ). BRAF and TP53 are associated with the